# A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children

> **NCT04070326** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 21 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** Lanadelumab

## Key facts

- **NCT ID:** NCT04070326
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-19
- **Primary completion:** 2021-10-30
- **Final completion:** 2021-10-30
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04070326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04070326, "A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04070326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*